KemPharm Alpha and Beta Analysis
| KMPHDelisted Stock | USD 5.81 0.02 0.34% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as KemPharm. It also helps investors analyze the systematic and unsystematic risks associated with investing in KemPharm over a specified time horizon. Remember, high KemPharm's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to KemPharm's market risk premium analysis include:
Beta 0.46 | Alpha 0.3 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
KemPharm |
KemPharm Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. KemPharm market risk premium is the additional return an investor will receive from holding KemPharm long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in KemPharm. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate KemPharm's performance over market.| α | 0.30 | β | 0.46 |
KemPharm Fundamentals Vs Peers
Comparing KemPharm's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze KemPharm's direct or indirect competition across all of the common fundamentals between KemPharm and the related equities. This way, we can detect undervalued stocks with similar characteristics as KemPharm or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of KemPharm's fundamental indicators could also be used in its relative valuation, which is a method of valuing KemPharm by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare KemPharm to competition |
| Fundamentals | KemPharm | Peer Average |
| Return On Equity | -0.31 | -0.31 |
| Return On Asset | -0.0897 | -0.14 |
| Operating Margin | (1.72) % | (5.51) % |
| Current Valuation | 97.06 M | 16.62 B |
| Shares Outstanding | 34.5 M | 571.82 M |
| Shares Owned By Insiders | 10.29 % | 10.09 % |
| Shares Owned By Institutions | 17.68 % | 39.21 % |
KemPharm Opportunities
KemPharm Return and Market Media
The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Meet KemPharms new CEO, a West Point grad who will lead the expansion into rare disease drugs | 02/02/2023 |
2 | Breakeven On The Horizon For KemPharm, Inc. | 02/09/2023 |
3 | CORRECTION KemPharm Announces Corporate Name Change to Zevra Therapeutics | 02/22/2023 |
4 | Zevra Therapeutics Announces Arimoclomol Research Featured in Two Poster Presentations at the 19th Annual WORLDSymposium 2023 | 02/24/2023 |
5 | Zevra Therapeutics to Report Fourth Quarter and Full-Year 2022 Results | 02/27/2023 |
About KemPharm Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including KemPharm or other delisted stocks. Alpha measures the amount that position in KemPharm has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
KemPharm Upcoming Company Events
As portrayed in its financial statements, the presentation of KemPharm's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, KemPharm's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of KemPharm's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of KemPharm. Please utilize our Beneish M Score to check the likelihood of KemPharm's management manipulating its earnings.
| 29th of March 2023 Upcoming Quarterly Report | View | |
| 11th of May 2023 Next Financial Report | View | |
| 31st of December 2022 Next Fiscal Quarter End | View | |
| 29th of March 2023 Next Fiscal Year End | View | |
| 30th of September 2022 Last Quarter Report | View | |
| 31st of December 2021 Last Financial Announcement | View |
Build Portfolio with KemPharm
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Other Consideration for investing in KemPharm Stock
If you are still planning to invest in KemPharm check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the KemPharm's history and understand the potential risks before investing.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |